Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urologic Diseases 1Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Hypogonadism 1

Interventions

Magnetic Resonance Spectroscopy 20enzalutamide 19apalutamide 17Prednisone 13Androgen Antagonists 13Abiraterone Acetate 13Specimen Handling 12abiraterone 8Radiotherapy 8Docetaxel 8Biopsy 8darolutamide 7Nivolumab 7cabazitaxel 6Radiosurgery 6Pluvicto 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6Lutetium-177 5radium Ra 223 dichloride 4gallium 68 PSMA-11 4cabozantinib 4bicalutamide 4atezolizumab 4Surveys and Questionnaires 4Standard of Care 4Radiotherapy, Intensity-Modulated 4Radiation 4Lutetium 4pembrolizumab 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × testosterone 17 beta-cypionate × 30 days × Clear all
NCT06305598 2026-05-15

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 1 Recruiting
14 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡